CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus
FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer
(mCRC).